Market Overview

Cantor Fitzgerald Initiates Coverage of Galena Biopharma with Buy Rating, $4 PT

Related GALE
Galena Biopharma Presents GALE-401 (Anagrelide Controlled Release) Clinical Trial Data At The 56th American Society of
UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided

In a report published earlier today, Cantor Fitzgerald L.P. initiated coverage of Galena Biopharma Inc. (NASDAQ: GALE) with a Buy rating and a $4.00 price target.

Cantor Fitzgerald went on to say “Galena Biopharma is a development-stage company with a clinical candidate, NeuVax, in Phase III testing for prevention of recurrence of breast cancer in women at high risk for recurrence. The concept of using medication to lower recurrence risk is not new (tamoxifen, aromatase inhibitors), but the targeted patient population - low HER2 expressers - represents a new paradigm in treating patients. The addressable market is sizable (multi-billion), but Galena and NeuVax's path to Phase III trials has been anything but straightforward. Nonetheless, the shares are modestly valued and incremental news flow combined with NeuVax's market opportunity makes the shares attractive.”

Galena Biopharma Inc. closed on Friday at $1.29.

Latest Ratings for GALE

DateFirmActionFromTo
Nov 2014MLV & Co.ReiteratesBuy
Nov 2014Cantor FitzgeraldMaintainsSell
Mar 2014McNicoll Lewis VlakMaintainsBuy

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Get Benzinga's Newsletters